We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Donors After Circulatory Death Heart Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03831048
Recruitment Status : Completed
First Posted : February 5, 2019
Last Update Posted : April 12, 2022
Information provided by (Responsible Party):

Tracking Information
First Submitted Date  ICMJE January 22, 2019
First Posted Date  ICMJE February 5, 2019
Last Update Posted Date April 12, 2022
Actual Study Start Date  ICMJE November 26, 2019
Actual Primary Completion Date April 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 21, 2019)
Survival [ Time Frame: 6 months ]
Patient survival 6 months post-transplant
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 21, 2019)
Utilization rate [ Time Frame: Within 24 hours post-transplant ]
The number of eligible DCD donor hearts that were instrumented on the OCS Heart System that meet the acceptance criteria for transplant divided by the total number of eligible DCD donor hearts that were instrumented on the OCS heart system
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures
 (submitted: May 21, 2019)
  • Patient and graft survival [ Time Frame: 30 days ]
    Patient and graft survival at 30 days post transplant
  • Patient and graft survival [ Time Frame: 30 days or hospital discharge, if later than 30 days ]
    Patient and graft survival at 30 days and initial hospital discharge, if later than 30 days
  • Severe heart primary graft dysfunction [ Time Frame: 24 hours post transplant ]
    Severe heart primary graft dysfunction of the left and/or right ventricle, not including rejection of cardiac tamponade
  • Post transplant Mechanical Circulatory Support (MCS) [ Time Frame: >72 hours immediately post-transplant ]
    Use of post-transplant mechanical circulatory support
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Donors After Circulatory Death Heart Trial
Official Title  ICMJE Clinical Trial to Evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Heart For Resuscitation, Preservation and Assessment of Hearts From Donors After Circulatory Death (DCD Heart Trial)
Brief Summary To evaluate the effectiveness of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
Detailed Description A prospective, randomized and concurrent controlled, non-inferiority pivotal trial in which subjects who receive a DCD donor heart transplant will be compared to subjects who receive a standard criteria donor heart transplant (Standard of Care 1 [SOC1] and Standard of Care 2 [SOC2] - from both randomized and concurrent control groups), adjusting for differences in risk factors.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Heart Transplant
Intervention  ICMJE
  • Device: OCS Heart System
    Preserving and assessing donor after circulatory death hearts for transplant
  • Other: Cold Storage
    Active comparator intervention
Study Arms  ICMJE
  • Experimental: DCD Heart Possible
    Intervention: Device: OCS Heart System
  • Active Comparator: Standard of Care Heart Only
    Intervention: Other: Cold Storage
Publications * Shudo Y, Benjamin-Addy R, Koyano TK, Hiesinger W, MacArthur JW, Woo YJ. Donors after circulatory death heart trial. Future Cardiol. 2021 Jan;17(1):11-17. doi: 10.2217/fca-2020-0070. Epub 2020 Jul 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 17, 2020)
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE September 28, 2021
Actual Primary Completion Date April 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Donor Inclusion

  • Maastricht Category III DCD donor, defined as expected death after the withdrawal of life- supportive therapy (WLST)
  • Donor age 18-49 years old inclusive
  • Warm ischemic time (WIT) ≤ 30 mins, with warm ischemic time defined as: Time from when mean systolic blood pressure (SBP) is < 50 mmHg or peripheral saturation < 70% to aortic cross-clamp and administration of cold cardioplegia in the donor.

Donor Exclusion

  • Previous cardiac surgery
  • Known coronary artery disease
  • Cardiogenic shock or myocardial infarction, or
  • Sustained terminal ejection fraction (EF) of ≤ 50%, or
  • Significant valve disease except for competent bicuspid aortic valve

Recipient Inclusion

  • Primary heart transplant candidates
  • Age ≥ 18 years old
  • Signed: (1) written informed consent document; (2) authorization to use and disclose protected health information; and (3) consent to TransMedics' use of recipients' United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation Network (OPTN) data and recipients' Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) data.

Recipient Exclusion

  • Prior solid organ or bone marrow transplant
  • Chronic use of hemodialysis or diagnosis of chronic renal insufficiency
  • Multi-organ transplant
  • Investigator unwilling to randomize to either arm.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03831048
Other Study ID Numbers  ICMJE OCS-CAR-03202019
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party TransMedics
Original Responsible Party [Redacted]
Current Study Sponsor  ICMJE TransMedics
Original Study Sponsor  ICMJE [Redacted]
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account TransMedics
Verification Date October 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP